期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 12, 期 3, 页码 473-488出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2011.552429
关键词
aripiprazole; bipolar depression; bipolar disorder; mania
资金
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Lundbeck
- Eli Lilly
- Jannssen
- Novartis
- Pfizer
- Sigma Tau
- Takeda
- Servier
Areas covered: This paper comprises a review and commentary regarding the use of oral and intramuscular aripiprazole in the acute and maintenance phases of bipolar disorder. Basic principles in dosing, switching, management of side effects and co-administration of aripiprazole with other medications are provided. This paper presents practical strategies to translate the data from clinical research into clinical practice. Expert opinion: Aripiprazole has proven to be an effective medication for the acute treatment of manic and mixed episodes, as well as for the prophylactic--maintenance phase of bipolar disorder in patients recovering from a manic/mixed episode. Choosing the appropriate dosing and tapering strategy, addressing the side effects, controlling withdrawal symptoms from previous medications and using adjunctive medications when necessary are key to successful treatment with aripiprazole.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据